🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06456814
Recruiting Observational

Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China

NCT06456814 · tracked via the Priya Life Science China tracker
Sponsor
Zhujiang Hospital
Phase
Observational
Started
2010-01-01
Last updated
2024-06-13

Condition(s) studied

Intracranial AneurysmSubarachnoid Hemorrhage, AneurysmalCerebral AneurysmBrain Aneurysm

Study summary

This is a retrospective, hospital-based and multi-center study aiming at investigating the potential exposures associated with the formation, progression, and rupture of intracranial aneurysms in Chinese population.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. IA diagnosis (ruptured or unruptured) or exclusion by digital subtractive angiography (DSA) or by cranial computed tomography angiography (CTA) / magnetic resonance angiography (MRA); 2. Aged ≥ 18 and ≤ 18 years old; 3. With complete demographic data including age and sex; 4. With medical record archiving officially. Exclusion Criteria: 1. Missing data of age, sex or hypertensive status; 2. Age \<18 or \>80 years; 3. Pregnancy; 4. With a history of intracranial arteriovenous malformation, Moyamoya, polycystic kidney disease, Ehlers-Danlos syndrome, Gronblad-Strandberg syndrome, or Marfan syndrome; 5. Suspicion for dissecting or mycotic aneurysms or aneurysm-like lesions that were indistinguishable from the infundibulum, fenestration, dilation, or atherosclerotic remodeling on structural imaging scans.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhujiang Hospital Guangzhou China Recruiting

More Zhujiang Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06456814 on ClinicalTrials.gov ↗ ← All trials in China